Bioextrax AB (SE:BIOEX)

:BIOEX

BIOEX

Bioextrax AB

RESEARCH TOOLSreports

Want to see SE:BIOEX full AI Analyst Report?

Bioextrax AB (BIOEX) Price & Analysis

0 Followers

BIOEX Stock Chart & Stats

kr3.19

kr0.10(3.70%)

At close: Mar 06 4:00 PM EST

kr3.19

kr0.10(3.70%)

Day’s Range― - ―

52-Week Rangekr1.60 - kr3.98

Previous CloseN/A

Volume15.49K

Average Volume (3M)82.14K

Market Cap

kr121.38M

Enterprise Valuekr107.58M

Total Cash (Recent Filing)kr3.93M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.80

Next Earnings

Aug 21, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.35

Shares Outstanding47,601,730

10 Day Avg. Volume104,394

30 Day Avg. Volume82,137

Financial Highlights & Ratios

PEG Ratio0.47

Price to Book (P/B)5.23

Price to Sales (P/S)146.53

P/FCF Ratio-4.23

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.37

Revenue Forecast (FY)kr2.34M

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetA zero-debt capital structure materially lowers refinancing and interest-rate risk, extending runway and giving management flexibility to pursue partnerships or licensing deals without near-term leverage constraints. This supports survival while R&D and commercialization progress.

Industrial Biotech Platform FocusA clear, specialized focus on biorefinery and bioactive compound extraction positions the company in structural demand trends toward sustainable, bio-based ingredients. Niche technical competence can create durable competitive advantage with industrial partners over a multi-quarter horizon.

Multiple Commercialization PathwaysA business model that supports product sales, licensing and contract R&D diversifies revenue levers and de-risks single-channel dependency. Licensing and milestone contracts can provide non-linear scaling and recurring/transactional cash alongside product commercialization over months to a few years.

Bears Say

Structurally Negative Gross ProfitNegative gross margins indicate the core process economics do not currently cover direct production costs, limiting sustainable scaling. Without durable gross-profit improvement, increased sales would not convert into operating profitability, threatening long-term viability.

Persistent Cash BurnConsistent negative operating and free cash flows with an accelerating 2025 burn raise the likelihood of external financing needs. Reliance on future funding can dilute equity and constrain long-term R&D or commercialization plans if capital markets tighten.

Eroding Equity From LossesDeclining equity and negative ROE reflect cumulative losses consuming shareholder capital. Persistent capital erosion reduces flexibility to fund operations internally and weakens the balance sheet buffer, increasing vulnerability if revenue fails to recover.

Bioextrax AB News

85X0 Earnings this Week: How Will it Perform?

Bioextrax AB (85X0) is scheduled to report 1st quarter earnings on 05/14/2026. Regarding Q1 estimates, Wall Street analysts...

9d ago

Is 85X0 a Buy, Before Earnings?

Bioextrax AB (85X0) is scheduled to report 4th quarter earnings on 02/19/2026. Regarding Q4 estimates, Wall Street analysts...

3M ago

BIOEX FAQ

What was Bioextrax AB’s price range in the past 12 months?

Bioextrax AB lowest stock price was kr1.60 and its highest was kr3.98 in the past 12 months.

What is Bioextrax AB’s market cap?

Bioextrax AB’s market cap is kr121.38M.

When is Bioextrax AB’s upcoming earnings report date?

Bioextrax AB’s upcoming earnings report date is Aug 21, 2026 which is in 92 days.

How were Bioextrax AB’s earnings last quarter?

Currently, no data Available

Is Bioextrax AB overvalued?

According to Wall Street analysts Bioextrax AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Bioextrax AB pay dividends?

Bioextrax AB does not currently pay dividends.

What is Bioextrax AB’s EPS estimate?

Bioextrax AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Bioextrax AB have?

Bioextrax AB has 47,601,730 shares outstanding.

What happened to Bioextrax AB’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Bioextrax AB?

Currently, no hedge funds are holding shares in SE:BIOEX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Bioextrax AB

Bioextrax AB (BIOEX) is a Swedish biotechnology company that focuses on developing and commercializing environmentally sustainable technologies for converting waste materials into valuable products. The company operates in the sectors of bio-based materials and waste management, offering innovative solutions for the production of bioplastics, animal feed, and other materials using its proprietary microbial processes.